BLOG

Cue Biopharma Pairs its Lead Candidate with Keytruda in Head and Neck Cancer Study

Cue Biopharma forged a clinical collaboration with Merck to combine its lead candidate CUE-101 with Merck‘s Keytruda as a first-line treatment for HPV+ recurrent/metastatic head and neck cancer.